SCHEMBL3368202

SCHEMBL3368202

[NH]C(=S)Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.52
CES2 O00748 1/20 0.52
AKR1B1 P15121 1/20 0.52
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
ALDH1A1 P00352 2/20 0.46
ALOX12 P18054 2/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 3/20 0.45
GAA P10253 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
MEN1 O00255 2/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1096270 0.80 CES1 (0.55) CES1CES2AKR1B1CA12CA1
SCHEMBL11389692 0.78 CES1 (0.52) CES1CES2AKR1B1ALDH1A1TSHR
SCHEMBL7765704 0.77 KEAP1 (0.54) CA12CA1CA2CA9ALDH1A1
SCHEMBL1397309 0.76 GAA (0.53) CES1CES2AKR1B1ALDH1A1ALOX12
SCHEMBL25675 0.76 CES1 (0.64) CES1CES2AKR1B1ALDH1A1TSHR
SCHEMBL3984107 0.76 CES1 (0.56) CES1CES2AKR1B1ALDH1A1ALOX12
SCHEMBL35280 0.76 CES1 (0.50) CES1CES2AKR1B1CA12CA1
SCHEMBL10971637 0.76 CA2 (0.52) CA12CA1CA2CA9ALDH1A1
SCHEMBL2424223 0.76 CES1 (0.50) CES1CES2AKR1B1CA12CA1
SCHEMBL4623008 0.76 CES1 (0.50) CES1CES2AKR1B1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142981-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-07-22 US claimed
US-20040110802-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-06-10 US claimed
WO-2004018428-A1 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
WO-2004018461-A2 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
EP-0754184-A1 CEPHALOSPORIN ANTIBIOTICS Microcide Pharmaceuticals, Inc. (US) 1997-01-22 EP claimed
WO-1995026966-A1 CEPHALOSPORIN ANTIBIOTICS MICROCIDE PHARMACEUTICALS, INC. (US) 1995-10-12 WO claimed
US-4407815-A AMINO ACID DERIVATIVE ANTIBIOTICS BEECHAM GROUP LIMITED (GB) 1983-10-04 US claimed
US-4342869-A Cephalosporin antibiotics MERCK & CO., INC. (US) 1982-08-03 US claimed
US-4338437-A Cephalosporin antibiotics MERCK & CO., INC. (US) 1982-07-06 US claimed
US-4338438-A Cephalosporin antibiotics MERCK & CO., INC. (US) 1982-07-06 US claimed
US-4297488-A 7-α-Methoxy cephalosporins MERCK & CO., INC. (US) 1981-10-27 US claimed
US-20100120896-A1 Once-A-Day RNA-Polymerase inhibiting and elongation factor G (EF-G) inhibiting antibiotic pharmaceutical product, formulation thereof, and use thereof in treating infection caused by methicillin-resistant staphylococcus aureus SHIONOGI INC. 2010-05-13 US disclosed
US-20100016333-A1 Once-a-day (RNA-Polymerase Inhibiting or phenazine) - dihydropteroate synthase inhibiting - dihydrofolate reductase inhibiting antibiotic pharmaceutical product, formulation thereof, and use thereof in treating infection caused by Methicillin-Resistant Staphylococcus aureus SHIONOGI INC. 2010-01-21 US disclosed
WO-2010005529-A2 ONCE-A-DAY RNA-POLYMERASE INHIBITING AND ELONGATION FACTOR G (EF-G) INHIBITING ANTIBIOTIC PHARMACEUTICAL PRODUCT, FORMULATION THEREOF, AND USE THEREOF IN TREATING INFECTION CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS MIDDLEBROOK PHARMACEUTICALS, INC. (US) 2010-01-14 WO disclosed
WO-2008021089-A2 ONCE-A-DAY (RNA-POLYMERASE INHIBITING OR PHENAZINE)-DIHYDROPTEROATE SYNTHASE INHIBITING-DIHYDROFOLATE REDUCTASE INHIBITING ANTIBIOTIC PHARMACEUTICAL PRODUCT, FORMULATION THEREOF, AND USE THEREOF IN TREATING INFECTION CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS MIDDLEBROOK PHARMACEUTICALS, INC. (US) 2008-02-21 WO disclosed
US-4056676-A ANTIBIOTIC ELI LILLY AND COMPANY (US) 1977-11-01 US disclosed
US-4056676-A ANTIBIOTIC ELI LILLY AND COMPANY (US) 1977-11-01 US disclosed
US-4052387-A METHOD OF PREPARATION OF 3-METHYLENECEPHAMS ELI LILLY AND COMPANY (US) 1977-10-04 US disclosed
US-4038275-A PROCESS FOR PREPARATION OF 3-HYDROXYMETHYLCEPHEMS ELI LILLY AND COMPANY (US) 1977-07-26 US disclosed
US-3907784-A 7-Halophenylthioacetamido cephalosporins LILLY CO ELI 1975-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142981-A1 Antibacterial benzoic acid derivatives GABRD, PHB1, GABBR1 CES1 2071/4885CES2 962/4885AKR1B1 2492/4885
US-20040110802-A1 Antibacterial benzoic acid derivatives GABRD, GABBR1, GABRA1 CES1 2190/4885CES2 1076/4885AKR1B1 3068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.